NCT/Study#

NCT04471844 /

EF-32

EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of ACTIVEly Diagnosed Glioblastoma

EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of ACTIVEly Diagnosed Glioblastoma

DISEASE GROUP:
Neuro-Oncology
current phase:
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: